Rituximab is a chimeric CD20 antibody that has been found to be effective for the treatment of B-cell lymphoma. It has a good safety profile and, hence, has been incorporated into many chemotherapeutic regimens for patients with B-cell lymphoma. We recently reported severe and prolonged IgM deficiency in myeloma patients who received rituximab infusion after autologous stem cell transplant (ASCT). 1 We observed increased infection rates in these patients. Patients with myeloma, however, usually have contracted B-cell repertoires. They already have depressed normal immunoglobulin levels even prior to any therapy. Therefore, the contracted B-cell repertoire may partly be responsible for the immunoglobulin deficiency. Here, we present data on patients with B-cell lymphoma who received rituximab after ASCT for highrisk disease to determine if immunoglobulin deficiency also occurs in these patients who were not previously immunoglobulin deficient.
Nine patients (seven men, two women) with high-risk B-cell lymphoma were evaluated. Their diagnoses were: advanced mantle cell lymphoma in first complete remission (CR1) (6), Stage IV diffuse large cell lymphoma in CR1 (1) and relapsed high-grade lymphoma in CR2 (2). The median age was 66 years (range 38-72 years). CR was achieved using R-CHOP (8) Unlike patients who underwent ASCT without rituximab, in whom B-cell recovery occurred between 3 and 6 months, [2] [3] [4] we observed severe delays in the immunoglobulin recoveries in these patients (Figure 1a ). At 9 months after transplant, all patients were IgM and IgG deficient, with only one patient who achieved a normal IgA level. At 24 months after transplant, all patients were still IgM deficient and only 20% achieved normal IgA and IgG levels. Severe immunoglobulin deficiency (o50% normal levels) in IgM were observed in all patients, in IgG and IgA in more than 20% patients (Figure 1b) , suggesting that the www.nature.com/bmt immunoglobulin recovery was both delayed and severely affected. These are in contrast to the recent report that rituximab administration after ASCT for B-cell lymphoma 5 affected primarily IgG. There are a number of possible explanations for the differences in our observations. Our patients received rituximab with the stem cell mobilization regimen. Therefore, the stem cells were likely severely depleted of B cells. The schedule of the antibody administration after transplant may also play a part. Although an identical number of rituximab infusions were given to the patients, instead of two 4-weekly blocks on Day þ 42 and Day þ 180, 5 we administered the antibody every 3 months throughout the 2-year period. The continuous B-cell depletion for 2 years probably severely delayed the immunoglobulin recovery.
The severe immunoglobulin deficiencies may be clinically relevant. One patient developed two episodes (follow-up 12 þ months), one seven episodes (follow-up 28 þ months) and another two episodes and a Vancomycin-sensitive chronic diarrhea (follow-up 18 þ months). All three patients had severe and prolonged immunoglobulin deficiencies. With a median follow-up of 28 months (range 13-32 months), all patients have remained lymphoma-free.
Our results, therefore, suggest that rituximab administration every 3 months after ASCT for high-risk B-cell lymphoma delays immunoglobulin recovery and may be associated with increased risk of infection. Although this approach may reduce lymphoma relapse, careful monitoring of the immunoglobulin recovery and intervention as appropriate should be done routinely in these patients. 
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